ACIDUM CLODRONICUM SINDRONAT 300 mg/5 ml CONC. FOR PERF. SOL. 300 mg/5 ml

Within this procedure, the intention is to purchase oncology medicines, according to the requirements and in the quantities provided in Annex no. 1 to the Specification, based on a framework agreement concluded with several economic operators (the bidders ranked in the top 3 places, for each lot separately) without reopening competition. If the number of participating economic operators who submitted admissible offers for a lot is less than 3, the Framework Agreement will be concluded with all those who submitted admissible offers. When two or more offers have the same financial proposal value and are ranked in the same place, the contracting authority will conclude the framework agreement with all economic operators ranked in the places corresponding to the maximum number (3) established, after the re-offering stage. The method of concluding subsequent contracts will be according to clauses 3.1.3 – 3.1.6 of the framework agreement. The estimated value of the largest subsequent contract anticipated to be awarded during the framework agreement: according to annex 1 to the Specification. Estimates of the minimum and maximum quantities that could be requested during the entire framework agreement: - minimum quantities according to annex 1 to the specification. - maximum quantities according to annex 1 to the specification. Estimated calendar (frequency and value of contracts to be awarded): quarterly The dates proposed in the estimated calendar represent the intention of the Contracting Authority - the buyer, not a firm commitment from the Contracting Authority - the buyer regarding the award of subsequent contracts, starting from the working assumption that no unforeseeable events/circumstances will occur that could not be taken into account at the time of initiating the award procedure, and that the necessary financial resources will also be ensured.